Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 60.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 47,401 shares of the company’s stock after acquiring an additional 17,858 shares during the quarter. Intech Investment Management LLC’s holdings in Denali Therapeutics were worth $966,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of DNLI. Quest Partners LLC acquired a new position in shares of Denali Therapeutics during the third quarter worth about $73,000. PNC Financial Services Group Inc. lifted its stake in shares of Denali Therapeutics by 30.5% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock worth $77,000 after purchasing an additional 885 shares in the last quarter. KBC Group NV lifted its stake in shares of Denali Therapeutics by 75.8% during the fourth quarter. KBC Group NV now owns 6,334 shares of the company’s stock worth $129,000 after purchasing an additional 2,731 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company’s stock worth $142,000 after purchasing an additional 4,449 shares in the last quarter. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company’s stock worth $204,000 after purchasing an additional 2,436 shares in the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $14.43 on Friday. Denali Therapeutics Inc. has a 1 year low of $14.01 and a 1 year high of $33.33. The firm has a market capitalization of $2.10 billion, a PE ratio of -5.23 and a beta of 1.46. The stock has a fifty day moving average of $19.68 and a two-hundred day moving average of $23.62.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.08. Equities research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. dropped their target price on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. The Goldman Sachs Group dropped their target price on Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. B. Riley reaffirmed a “buy” rating and set a $35.00 target price (down from $38.00) on shares of Denali Therapeutics in a research report on Wednesday, March 5th. Morgan Stanley assumed coverage on Denali Therapeutics in a research report on Friday, March 7th. They set an “overweight” rating and a $33.00 target price on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Denali Therapeutics in a research report on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.20.

Insiders Place Their Bets

In other Denali Therapeutics news, insider Carole Ho sold 12,255 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the sale, the insider now directly owns 178,580 shares in the company, valued at approximately $3,610,887.60. The trade was a 6.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares in the company, valued at approximately $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is owned by corporate insiders.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.